As shown in Table 1 and Figure 2, myeloma patients had a significant increase in plasma osteopontin level during apheresis, but the increase in median osteopontin level 24 h after apheresis did not reach statistical significance. This evidence concerns the gene SPP1 and plasma cell myeloma.